UK competition watchdog accuses Merck of obstructing biosimilars

LONDON (Reuters) - Britain's competition watchdog on Tuesday accused Merck & Co of operating an anti-competitive discount scheme for its medicine Remicade, designed to restrict competition from so-called biosimilar copies of the drug.